Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,350 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Abnormalities Clear all
Recruiting Not applicable Interventional

Milk for Diabetes Prevention

NCT06513026
View directory record Official record
Conditions
Lactose Intolerance, Lactose Intolerant, Lactase Persistence, Pre-Diabetes, Diabetes Mellitus, Type 2
Interventions
Lactose-Containing Milk, Lactose-Free Milk
Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 28, 2026, 4:16 AM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess Safety and Efficacy of ANG003

NCT06052293
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
ANG003
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 28, 2026, 4:16 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00332215
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Sodium Pyruvate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 28, 2026, 4:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

NCT02947087
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Prolastin-C, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 28, 2026, 4:16 AM EDT
Terminated Phase 4 Interventional Results available

Aralast alpha1-proteinase Inhibitor Surveillance Study

NCT00313144
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
ARALAST Alpha1-Proteinase Inhibitor
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Marino, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 28, 2026, 4:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Collection From Individuals With Lung Disease for Genetic Studies

NCT00362739
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
3,087 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 28, 2026, 4:16 AM EDT
Completed No phase listed Observational

AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry

NCT01974830
View directory record Official record
Conditions
Alpha-1 Anti-trypsin Deficiency
Interventions
Not listed
Lead sponsor
Coram Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 2 Interventional

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

NCT03770637
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
Glucagon RTU, Placebo
Drug · Other
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Not applicable Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS

NCT00002273
View directory record Official record
Conditions
Colitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 1 Interventional

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

NCT03518554
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
Interventions
JAB-3068
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT04058366
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 1 Interventional Results available

Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency

NCT00430768
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
rAAV1-CB-hAAT
Biological
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Gainesville, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 28, 2026, 4:16 AM EDT
Not listed No phase listed Observational

Pulmonary Health in Children With Down Syndrome

NCT04398862
View directory record Official record
Conditions
Down Syndrome, Dysphagia, Oropharyngeal
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 28, 2026, 4:16 AM EDT
Terminated Not applicable Interventional Results available

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NCT01319851
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 28, 2026, 4:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Association Between Lactase Deficiency, and the Small Intestinal Microbiome in Adults.

NCT03860051
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 28, 2026, 4:16 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

NCT00301366
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
alpha-1 proteinase inhibitor (human)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 28, 2026, 4:16 AM EDT
Completed No phase listed Observational Results available

IL-17 Neutrophils in CF Lung Inflammation

NCT02025829
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 28, 2026, 4:16 AM EDT
Recruiting No phase listed Observational

Prostate Cancer Genetic Risk Evaluation and Screening Study

NCT05129605
View directory record Official record
Conditions
Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions
Prostate cancer screening
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 74 Years · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 28, 2026, 4:16 AM EDT
Recruiting Phase 2 Interventional

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 4:16 AM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 28, 2026, 4:16 AM EDT